

## **SUMMARY OF PRODUCT CHARACTERISTICS**

### **1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

**Protect Flea and Worm Treatment tablets for medium dogs**  
11.5 mg/ 230 mg film-coated tablets

### **2. QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each tablet contains:

#### **Active substances**

Milbemycin oxime	11.5 mg
Lufenuron	230.0 mg

Excipient:

Titanium dioxide (E171)	3.7 mg
-------------------------	--------

For a full list of excipients, see section 6.1.

### **3. PHARMACEUTICAL FORM**

Film-coated tablets

White, pentagonal, biconvex, bevel-edged, coated tablets with "GLG" on one side and "CGV" on the reverse.

### **4. CLINICAL PARTICULARS**

#### **4.1 Target species**

Dogs

#### **4.2 Indications for use, specifying the target species**

Protect Flea and Worm Treatment is used for the prevention of fleas (*Ct. felis*, *Ct. canis*, preadult stages), and for the concurrent prevention of heartworm (elimination of L3/L4 larval stages of *Dirofilaria immitis*) and/or treatment of adult stages of gastrointestinal nematodes such as hookworms (*Ancylostoma caninum*), roundworms (*Toxocara canis*) and whipworms (*Trichuris vulpis*).

#### **4.3 Contraindications**

Do not use in case of hypersensitivity to the active substance, to the adjuvants or to any of the excipients.

#### 4.4 Special warnings

Ideally, tablets are administered on the same day each month. If an interval is greater than 6 weeks, treatment should be resumed immediately and be continued at monthly intervals and, in case of heartworm prevention, a veterinarian should be consulted.

#### 4.5 Special precautions for use

i. Special precautions for use in animals

In heartworm risk regions, or in case it is known that a dog has been travelling to and from heartworm risk regions, before commencing Protect Flea and Worm Treatment, as with any other heartworm preventive, a veterinary consultation is advised to exclude the presence of any concurrent infestation of *Dirofilaria immitis*. In the case of a positive diagnosis, adulticidal therapy is indicated before administering Protect Flea and Worm Treatment.

ii. Special precautions to be taken by the person administering the veterinary medicinal product to animals

None.

In the case of accidental ingestion seek medical advice immediately and show the package leaflet or the label to the physician.

#### 4.6 Adverse reactions (frequency and seriousness)

Pale mucous membranes, increased intestinal peristalsis, lethargy, diarrhea have been observed very rarely after treatment. The treatment of dogs with a high number of circulating microfilariae can sometimes lead to the appearance of moderate and transitory hypersensitivity reactions, such as pale mucous membranes, vomiting, laboured breathing, or excessive salivation. These reactions are associated with the release of proteins from dead or dying microfilariae and are not a direct toxic effect of the product.

#### 4.7 Use during pregnancy, lactation or lay

Pregnancy:

Can be used during pregnancy.

Lactation:

Can be used during lactation.

#### 4.8 Interaction with other medicinal products and other forms of interaction

During treatment with Protect Flea and Worm Treatment, no other antiparasitic macrocyclic lactones should be administered.

#### 4.9 Amounts to be administered and administration route

Protect Flea and Worm Treatment tablets, available in four sizes, are given according to the weight of the dog, consistent with the administration of a minimum dose of 0.5 mg milbemycin oxime and 10 mg lufenuron per kg body weight.

Colour of container	Body weight (kg)	Posology	mg of milbemycin per tablet	mg of lufenuron per tablet
yellow	from 12 to 22 kg	1 tablet/month	11.5	230

Protect Flea and Worm Treatment should be administered in the following situations:

##### Puppies:

To prevent flea infestations with concurrent heartworm prevention and/or gastrointestinal nematode infection treatment should start from 2 weeks of age, or from a minimum weight of 1 kg.

##### Dogs in a non-heartworm region:

Protect Flea and Worm Treatment can be used as part of the seasonal prevention of fleas replacing lufenuron mono (PROGRAM tablets) in cases with diagnosed concurrent gastrointestinal nematode infection. After elimination of the nematode infection confirmed by faecal examination, prevention of fleas should continue with PROGRAM tablets if indicated.

In puppies, treatment with Protect Flea and Worm Treatment is recommended up to one month after weaning. Thereafter, prevention of fleas can be continued with lufenuron mono (Program).

##### Dogs travelling to a heartworm region:

To prevent flea infestations with concurrent heartworm prevention, dogs travelling to a heartworm risk region should begin medication within one month after arrival. Treatment should continue monthly, with the last administration given after the dog has left the region.

##### Dogs in a heartworm region:

To prevent flea infestations and to prevent heartworm, medication should begin within one month after the appearance of mosquitoes, or one month before the appearance of fleas, and continue throughout the risk period with

the last dose given within one month after the mosquito and flea season finishes.

If dogs have a high level of flea infestation at the start of treatment, it may be necessary to apply a flea adulticide during the first one to two months. It is important to treat all dogs and cats in the household for fleas. Cats in the same household should be treated with PROGRAM oral or injectable suspension.

#### **4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary**

At 10x recommended dose rate (i.e. 5 mg milbemycin oxime, 100 mg lufenuron per kg) and higher dose rates clinical signs such as transient ataxia, trembling, depression, salivation, and mydriasis may be observed. There is no specific antidote.

#### **4.11 Withdrawal period(s)**

Not applicable.

### **5. PHARMACOLOGICAL PROPERTIES**

**Pharmacotherapeutic group:** Milbemycin oxime Anthelmintic, Lufenuron Insect Growth Regulator

**ATC Vet Code:** QP54AB51

#### **5.1 Pharmacodynamic properties**

Milbemycin belongs to the group of macrocyclic lactones, isolated from the fermentation of *Streptomyces hygroscopicus* var. *aureolacrimosus*. Out of the selected analogues, the one currently used for medicinal purposes is Milbemycin A3/A4 oxime (ratio x20 : x80). As one of the active principles in Protect Flea and Worm Treatment, it is effective against larval stages (L3, L4, and the microfilariae) of *Dirofilaria immitis*, and anthelmintic activity against the following nematodes: *Toxocara canis*, *Trichuris vulpis*, *Ancylostoma caninum*. The activity of milbemycin is correlated with its action on invertebrate neurotransmission: it potentiates GABA (gamma-amino-butyric acid), an inhibitor of neuromuscular transmission, leading to paralysis.

Lufenuron belongs to the chemical group of benzoylureas, and is considered an IGR (Insect Growth Regulator) or IDI (Insect Development Inhibitor). It inhibits the development of fleas by interfering with the normal synthesis, polymerisation and deposition of the chitin, the principal component of the arthropod exoskeleton. The adult flea absorbs lufenuron via its bloodmeal. At therapeutic levels, lufenuron has no effect upon adult fleas, but passes transovarially to act upon certain stages of the development of the insect (egg and larva), thus interrupting the insect life cycle. Also, adult flea faeces

containing lufenuron exert a larvicidal effect when ingested by the larvae directly.

## **5.2 Pharmacokinetic particulars**

Milbemycin oxime is characterised by gastro-enteric absorption. It reaches peak plasma concentrations of about 200 - 300 ng/mL within about 2 to 5 hours after oral administration at recommended dose. Thereafter, milbemycin oxime concentrations decrease in plasma with a half life of about 1 to 3 days. Following oral administration, lufenuron is distributed via the blood to the adipose tissue, from which, metabolically unmodified, it is constantly released above the minimum effective concentration for at least one month.

## **6. PHARMACEUTICAL PARTICULARS**

### **6.1 List of excipients**

Titanium dioxide (E171)  
Macrogol 8000  
Cellulose, microcrystalline  
Lactose monohydrate  
Pregelatinised maize starch  
Croscarmellose sodium  
Hypromellose  
Talc  
Magnesium stearate

### **6.2 Incompatibilities**

None known.

### **6.3 Shelf life**

Shelf-life of the veterinary medicinal product as packaged for sale: 5 years.

### **6.4 Special precautions for storage**

Do not store above 25°C  
Keep the blister strips in the outer carton.

### **6.5 Nature and composition of immediate packaging**

Carton containers, each containing 6 or 8 pentagonal tablets in PVDC/PVC blisters, thermosealed with aluminium foil, boxed in a free-opening, labelled carton.

Not all pack sizes may be marketed.

**6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products**

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

**7. MARKETING AUTHORISATION HOLDER**

Elanco Europe Ltd  
Lilly House  
Priestley Road  
Basingstoke  
Hampshire  
RG24 9NL

**8. MARKETING AUTHORISATION NUMBER**

Vm 00879/4087

**9. DATE OF FIRST AUTHORISATION**

23 June 2014

**10. DATE OF REVISION OF THE TEXT**

November 2016

A handwritten signature in black ink, appearing to be 'Alan', with a horizontal line underneath.

Approved: 08 November 2016